Abstract
Aims: 1. To identify the treatment costs of different standard fluoropyrimidine-based therapies, i. e. the Mayo Clinic and AIO/Ardalan regimens, under real-life conditions in settings routinely used for chemotherapy administration in Germany (inpatient, day-clinic or office-based oncologists). 2. To investigate the cost implications of routine use of capecitabine, an oral alternative for the treatment of metastatic colorectal cancer. Method: Analysis of actual fee-listings of office based oncologists and projection of results to several hospital-based treatment settings and to oral treatment with capecitabine. Results: Office-based setting: The highest quarterly treatment costs of 9,874 € were found for the AIO/Ardalan-regimen, followed by the Mayo Clinic-regimen, which incurred costs of 2,497 € The cheapest treatment option was capecitabine with quarterly costs of 1,610 €. Day-clinic setting: The costs of the Mayo-Clinic protocol amounted to 2,036 € in a municipal hospital and 8,455 € in an university hospital. The respective costs for the AlO/Ardalan regime were 1,294 € and 5,374 €. In-patient setting: Mayo-Clinic protocol costs were 3,143 € in a municipal hospital and 10,569 € in a university hospital. Respective costs found for the AIO/Ardalan-regimen were 1,998 € and 6,717 € Conclusion: From a pharmacoeconomic perspective, substantial cost savings for health insurances, without inducing losses by providers, may be realized, if patients are transferred from the hospital to the office-based setting and treated with capecitabine Further savings could be realized if drug prices in hospital and retail pharmacies were harmonized.
Translated title of the contribution | Treatment costs of fluoropyrimidine-based therapies of colorectal cancer in different treatment settings in Germany |
---|---|
Original language | German |
Pages (from-to) | 229-235 |
Number of pages | 7 |
Journal | Gesundheitsokonomie und Qualitatsmanagement |
Volume | 9 |
Issue number | 4 |
DOIs | |
State | Published - Aug 2004 |
Keywords
- Colorectal cancer
- Germany
- Oral administration
- Treatment costs
- Treatment setting
ASJC Scopus subject areas
- Health Policy